ABG Sundal Collier acted as Sole Global Coordinator and Bookrunner in connection with the SEK 30 million directed share issue in Ascelia Pharma

On September 22, 2025, Ascelia Pharma announced the successful completion of a directed issue of approximately 8.5 million shares at a price of SEK 3.50, raising gross proceeds of SEK 30m. The Company plans to use the net proceeds to further strengthen its balance sheet, supporting partnering activities, and to extend cash runway into Q4 2026 past the expected timing of the US Food and Drug Administration (FDA) response on the newly submitted New Drug Application (NDA) (announced on September 3, 2025).